HK1221656A1 - σ受体配体在预防和治疗与间质性膀胱炎/膀胱疼痛综合征(IC/BPS)相关疼痛中的应用 - Google Patents

σ受体配体在预防和治疗与间质性膀胱炎/膀胱疼痛综合征(IC/BPS)相关疼痛中的应用 Download PDF

Info

Publication number
HK1221656A1
HK1221656A1 HK16109869.1A HK16109869A HK1221656A1 HK 1221656 A1 HK1221656 A1 HK 1221656A1 HK 16109869 A HK16109869 A HK 16109869A HK 1221656 A1 HK1221656 A1 HK 1221656A1
Authority
HK
Hong Kong
Prior art keywords
bps
prevention
treatment
interstitial cystitis
receptor ligands
Prior art date
Application number
HK16109869.1A
Other languages
English (en)
Chinese (zh)
Inventor
José-Miguel Vela-Hernández
Manuel Merlos-Roca
José-Manuel Baeyens-Cabrera
Cruz-Miguel Cendán-Martínez
Original Assignee
Laboratorios Del Dr. Esteve, S.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Del Dr. Esteve, S.A filed Critical Laboratorios Del Dr. Esteve, S.A
Publication of HK1221656A1 publication Critical patent/HK1221656A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK16109869.1A 2013-06-26 2014-06-25 σ受体配体在预防和治疗与间质性膀胱炎/膀胱疼痛综合征(IC/BPS)相关疼痛中的应用 HK1221656A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382246.0A EP2818166A1 (en) 2013-06-26 2013-06-26 Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
EP20130382246 2013-06-26
PCT/EP2014/063360 WO2014207024A1 (en) 2013-06-26 2014-06-25 Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)

Publications (1)

Publication Number Publication Date
HK1221656A1 true HK1221656A1 (zh) 2017-06-09

Family

ID=48700506

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16109869.1A HK1221656A1 (zh) 2013-06-26 2014-06-25 σ受体配体在预防和治疗与间质性膀胱炎/膀胱疼痛综合征(IC/BPS)相关疼痛中的应用

Country Status (19)

Country Link
US (1) US20160151377A1 (cg-RX-API-DMAC7.html)
EP (2) EP2818166A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016523276A (cg-RX-API-DMAC7.html)
KR (1) KR20160023839A (cg-RX-API-DMAC7.html)
CN (1) CN105377257A (cg-RX-API-DMAC7.html)
AR (1) AR096709A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014301220A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015032343A8 (cg-RX-API-DMAC7.html)
CA (1) CA2916568A1 (cg-RX-API-DMAC7.html)
HK (1) HK1221656A1 (cg-RX-API-DMAC7.html)
IL (1) IL243362A0 (cg-RX-API-DMAC7.html)
MA (1) MA38711A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015017761A (cg-RX-API-DMAC7.html)
PH (1) PH12015502815A1 (cg-RX-API-DMAC7.html)
RU (1) RU2016102149A (cg-RX-API-DMAC7.html)
SG (1) SG11201510408XA (cg-RX-API-DMAC7.html)
TN (1) TN2015000558A1 (cg-RX-API-DMAC7.html)
TW (1) TWI629984B (cg-RX-API-DMAC7.html)
WO (1) WO2014207024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
MX2016007286A (es) * 2013-12-17 2016-08-04 Esteve Labor Dr Combinaciones de gabapentinoides y ligandos de receptores sigma.
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR20250116520A (ko) 2024-01-25 2025-08-01 가톨릭대학교 산학협력단 칸나비디올을 유효성분으로 포함하는 방광 통증 증후군의 예방 또는 치료용 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335668B2 (en) * 2001-07-10 2008-02-26 Astellas Pharma Inc. Pharmaceutical composition for therapy of interstitial cystitis
KR101352012B1 (ko) 2004-08-27 2014-01-15 라보라토리오스 델 드라. 에스테브.에스.에이. 시그마 수용체 저해제
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
US20090325975A1 (en) * 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
CN101395157A (zh) * 2006-03-01 2009-03-25 伊斯特芬博士实验室有限公司 作为西格玛受体抑制剂的吡唑衍生物
WO2007098953A1 (en) * 2006-03-01 2007-09-07 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2460804A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del Dr. Esteve, S.A. 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
NZ618795A (en) * 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain

Also Published As

Publication number Publication date
AU2014301220A1 (en) 2016-02-18
BR112015032343A2 (pt) 2017-09-26
BR112015032343A8 (pt) 2018-01-23
EP3013338A1 (en) 2016-05-04
SG11201510408XA (en) 2016-01-28
MA38711A1 (fr) 2017-12-29
WO2014207024A1 (en) 2014-12-31
IL243362A0 (en) 2016-02-29
TWI629984B (zh) 2018-07-21
CA2916568A1 (en) 2014-12-31
RU2016102149A (ru) 2017-08-02
US20160151377A1 (en) 2016-06-02
TW201536295A (zh) 2015-10-01
KR20160023839A (ko) 2016-03-03
RU2016102149A3 (cg-RX-API-DMAC7.html) 2018-05-25
TN2015000558A1 (en) 2017-04-06
CN105377257A (zh) 2016-03-02
MX2015017761A (es) 2016-07-06
JP2016523276A (ja) 2016-08-08
AR096709A1 (es) 2016-01-27
EP2818166A1 (en) 2014-12-31
PH12015502815A1 (en) 2016-03-21

Similar Documents

Publication Publication Date Title
PH12015502815A1 (en) Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)
EP3068289A4 (en) Prevention and treatment of bed exits, falls, and other conditions
DK3791896T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
IL239981A0 (en) Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
EA201691619A1 (ru) Конденсированные гетероциклические соединения
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
NZ732511A (en) Small molecule inhibitors of egfr and pi3k
IL248130A0 (en) Isoindolinone compounds as gpr119 regulators in the treatment of diabetes, obesity, dyslipidemia and related diseases
EP3065768A4 (en) Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
IL240599A0 (en) Combined treatment to treat the formation of acne
IL248118A0 (en) Converted inanone compounds as gpr119 regulators for the treatment of diabetes, obesity, dyslipidemia and related diseases
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
PT3164125T (pt) Métodos e composições para tratar obesidade, prevenir ganho de peso, promover perda de peso, promover emagrecimento ou tratar ou prevenir o desenvolvimento de diabetes
HK1221150A1 (zh) 用二氢吡嗪并-吡嗪类对癌症的治疗
NZ722600A (en) Methods of treating mild brain injury
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
SMT202500016T1 (it) Trattamento di pazienti affetti da malattia di fabry aventi determinate mutazioni
WO2014009738A3 (en) Treatment of muscular dystrophy
HK1242581A1 (en) Use of sigma receptor ligands in osteoarthritis
GB2546703A (en) Compounds